» Articles » PMID: 39867175

Nationwide Outcomes of Heart Transplantation for Postpartum Cardiomyopathy

Overview
Date 2025 Jan 27
PMID 39867175
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Postpartum cardiomyopathy is defined as an incident of acute heart failure in the postpartum period in the absence of any other cause. Up to 10% of postpartum cardiomyopathy may need to undergo heart transplantation later in life. This study aimed to provide a present-day perspective on all-cause mortality and transplant-related complications after heart transplantation for postpartum cardiomyopathy.

Methods: A retrospective analysis of the United Network for Organ Sharing (UNOS) registry was performed for adult patients undergoing heart transplants (01/2001-01/2023) for postpartum cardiomyopathy.

Results: A total of 677 patients were identified, with a mean age of 35 years. The mean body mass index (BMI) was 27.2 kg/m; the most common comorbidity was type 2 diabetes (T2D) (n = 589; 87%). Older age was associated with lower overall mortality (hazard ratio (HR): 0.97; 95% CI: 0.95, 0.98; < 0.01), while diabetes (HR: 1.01; 95% CI: 1.01, 1.01; < 0.01), dialysis (HR: 1.01; 95% CI: 1.01, 1.01; < 0.01), days on Status 1 on the UNOS registry (HR: 1.06; 95% CI: 1.03, 10.9; < 0.01), creatinine (HR: 1.29; 95% CI: 1.02, 1.64; = 0.034), and length of stay (HR: 1.01; 95% CI: 1.01, 1.02; = 0.02) were associated with a higher risk of overall mortality. Moreover, 30-day mortality was 2.8%, and 1-year mortality was 11.1%. The era effect was prominent in cases of 1-year mortality (odds ratio (OR): 0.95; 95% CI: 0.91, 0.99, = 0.006).

Conclusions: Our results suggest that younger age, diabetes, pretransplant dialysis, days on Status 1, and creatinine are associated with higher mortality, while an era effect was observed for 1-year mortality after heart transplantation (HTx) in patients with postpartum cardiomyopathy.

References
1.
Kwon J, Tedford R, Ramu B, Witer L, Pope N, Houston B . Heart Transplantation for Peripartum Cardiomyopathy: Outcomes Over 3 Decades. Ann Thorac Surg. 2022; 114(3):650-658. DOI: 10.1016/j.athoracsur.2021.12.059. View

2.
Bouabdallaoui N, Demondion P, Marechaux S, Varnous S, Lebreton G, Mouquet F . Heart Transplantation for Peripartum Cardiomyopathy: A Single-Center Experience. Arq Bras Cardiol. 2018; 110(2):181-187. PMC: 5855912. DOI: 10.5935/abc.20180014. View

3.
McNamara D, Elkayam U, Alharethi R, Damp J, Hsich E, Ewald G . Clinical Outcomes for Peripartum Cardiomyopathy in North America: Results of the IPAC Study (Investigations of Pregnancy-Associated Cardiomyopathy). J Am Coll Cardiol. 2015; 66(8):905-14. PMC: 5645077. DOI: 10.1016/j.jacc.2015.06.1309. View

4.
Rasmusson K, Stehlik J, Brown R, Renlund D, Wagoner L, Torre-Amione G . Long-term outcomes of cardiac transplantation for peri-partum cardiomyopathy: a multiinstitutional analysis. J Heart Lung Transplant. 2007; 26(11):1097-104. DOI: 10.1016/j.healun.2007.08.002. View

5.
Mielniczuk L, Williams K, Davis D, Tang A, Lemery R, Green M . Frequency of peripartum cardiomyopathy. Am J Cardiol. 2006; 97(12):1765-8. DOI: 10.1016/j.amjcard.2006.01.039. View